Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Salmeterol plus theophylline combination therapy in the treatment of COPD
Autore:
ZuWallack, RL; Mahler, DA; Reilly, D; Church, N; Emmett, A; Rickard, K; Knobil, K;
Indirizzi:
St Francis Hosp & Med Ctr, Sect Pulm Med, Hartford, CT 06105 USA St Francis Hosp & Med Ctr Hartford CT USA 06105 d, Hartford, CT 06105 USA Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA Dartmouth Hitchcock MedCtr Lebanon NH USA 03766 r, Lebanon, NH 03766 USA Glaxo Wellcome Inc, Res Triangle Pk, NC 27709 USA Glaxo Wellcome Inc Res Triangle Pk NC USA 27709 Triangle Pk, NC 27709 USA
Titolo Testata:
CHEST
fascicolo: 6, volume: 119, anno: 2001,
pagine: 1661 - 1670
SICI:
0012-3692(200106)119:6<1661:SPTCTI>2.0.ZU;2-T
Fonte:
ISI
Lingua:
ENG
Soggetto:
OBSTRUCTIVE PULMONARY-DISEASE; AIR-FLOW OBSTRUCTION; QUALITY-OF-LIFE; IPRATROPIUM BROMIDE; EXERCISE PERFORMANCE; ORAL THEOPHYLLINE; INHALED SALMETEROL; RESPIRATORY MUCOSA; REDUCES DYSPNEA; LUNG-FUNCTION;
Keywords:
chronic bronchitis; combination therapy; COPD; dyspnea; emphysema; exacerbations; FEV1; quality of life;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
53
Recensione:
Indirizzi per estratti:
Indirizzo: ZuWallack, RL St Francis Hosp & Med Ctr, Sect Pulm Med, 114 Woodland St, Hartford, CT 06105 USA St Francis Hosp & Med Ctr 114 Woodland St Hartford CTUSA 06105
Citazione:
R.L. ZuWallack et al., "Salmeterol plus theophylline combination therapy in the treatment of COPD", CHEST, 119(6), 2001, pp. 1661-1670

Abstract

Background: Patients with COPD often require multiple therapies to improvelung function and decrease symptoms and exacerbations. Salmeterol and theophylline are indicated for the treatment of COPD, but the use of these agents in combination has not been extensively studied. Objectives: To compare the efficacy and safety of salmeterol plus theophylline vs either agent alone in COPD,Methods: Randomized, double-blind, double-dummy, parallel-group trial in 943 patients with COPD. lifter an open-label theophylline titration period (serum levels, 10 to 20 mug/mL), patients were randomly assigned to receive salmeterol (42 mug bid) plus theophylline, salmeterol (42 IJ g bid), or theophylline for 12 weeks. Serial pulmonary function tests were completed on day 1 and treatment week 12, Patients kept diary cards and noted their peak flow rates, symptom scores, and albuterol use, and periodically completed quality-of-life and dyspnea questionnaires. Results: All three groups significantly improved compared with baseline. Combination treatment with salmeterol plus theophylline provided significantly (p less than or equal to 0.045) greater improvements in pulmonary function; significantly (p less than or equal to 0.048) greater decreases in symptoms, dyspnea, and albuterol use; and significantly fewer COPD exacerbations (p = 0.023 vs theophylline), In general, treatment with salmeterol provided greater improvement in lung function and satisfaction with treatment compared with theophylline, Salmeterol treatment was also associated with significantly fewer drug-related adverse events (p less than or equal to 0.042)than either treatment that included theophylline, The safety profile (adverse events, vital signs, and ECG findings) of the two treatments that included theophylline were similar. Conclusion: Patients with COPD may benefit from combination treatment withsalmeterol plus theophylline without a resulting increase in adverse events or other adverse sequelae.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 12/07/20 alle ore 13:04:33